Reaction

Immunisation reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 428 reports · 45 co-occurring drugs

As of the last recalculation, Immunisation appears in 428 FAERS reports alongside 45 co-occurring drug terms. The strongest observed disproportionality signal is FELODIPINE EXTENDED-RELEASE TABLETS (PRR 2,718.5).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
DrugCo-reportsPRRROR
Felodipine Extended-Release Tablets2562,718.52,781.4
Felodipine2562,718.32,781.1
Amitriptyline Hydrochloride2561,764.31,790.5
Linagliptin2551,680.71,704.6
Isosorbide Dinitrate2451,425.91,444.1
Isosorbide Mononitrate2431,317.01,332.7
Dapagliflozin255973.9981.9
Apixaban262489.4491.3
Cetirizine Hydrochloride Allergy173465.6468.3
Cetirizine Hydrochloride Tablets173465.5468.2
Esomeprazole244443.7445.5
Digoxin258438.7440.3
Candesartan176406.8408.8
Cetirizine255393.9395.2
Naproxen256392.9394.2
Bisoprolol Fumarate264245.0245.5
Candesartan Cilexetil101244.2245.1
Levothyroxine Sodium Anhydrous229237.9238.5
Naproxen Sodium256215.3215.7
Hydrochlorothiazide257213.9214.2
Esomeprazole Magnesium Capsule, Delayed Release54207.0207.7
Esomeprazole Magnesium Delayed Release Capsules54207.0207.7
Esomeprazole Magnesium Dihydrate54206.1206.8
Cetirizine Hydrochloride257188.2188.5
Lansoprazole261181.1181.4
Cetiirizine96141.8142.1
Simvastatin260127.2127.3
Losartan220124.9125.1
Esomeprazole Magnesium250123.5123.6
Bumetanide49101.8101.9
Fexofenadine3094.995.1
Sotalol Hydrochloride2990.991.1
Omeprazole24579.579.5
Levothyroxine Sodium23176.576.5
Insulin Glargine-Yfgn2969.169.2
Docusate Sodium 100Mg2860.960.9
Doxazosin2954.054.0
Fluticasone Propionate Nasal2949.849.9
Senna Leaf2044.244.2
Sennosides 8.6 Mg Tablets1843.643.6
Senna1843.343.3
Sildenafil Powder,2942.442.5
Doxazosin Mesylate2941.841.9
Lactulose2939.439.4
Warfarin Sodium3033.733.8

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.